Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals demonstrated a solid financial performance, ending the fourth quarter of 2025 with $2.67 billion in cash and equivalents, an increase from $2.24 billion in the previous quarter. The company anticipates revenue growth to outpace operational expense increases, driven primarily by successful product launches and strong demand, particularly for their familial chylomicronemia syndrome (FCS) drug, which saw a 56% quarter-over-quarter revenue increase. Additionally, the positive momentum is bolstered by projected milestones from ongoing clinical trials and the submission of supplemental new drug applications, positioning Ionis for a promising growth trajectory in 2026.

Ionis Pharmaceuticals is experiencing a negative outlook primarily due to significant anticipated revenue declines, particularly with the upcoming price adjustments for its drug Tryngolza ahead of a broader market launch in 2026. The company is forecasting total revenues of $800-825 million for 2026, which falls short of analyst expectations of $914 million, alongside non-GAAP operating losses projected at $500-550 million, exceeding the consensus estimate of $399 million. Additionally, ongoing risk factors, including slower market uptake, regulatory delays, and competitive pressures, particularly in the rare disease and cardiovascular treatment markets, further exacerbate financial concerns for Ionis Pharmaceuticals.